MXPA04003674A - Uso mejorado de compuesto antitumoral en terapia de cancer. - Google Patents

Uso mejorado de compuesto antitumoral en terapia de cancer.

Info

Publication number
MXPA04003674A
MXPA04003674A MXPA04003674A MXPA04003674A MXPA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A MX PA04003674 A MXPA04003674 A MX PA04003674A
Authority
MX
Mexico
Prior art keywords
cancer therapy
improved use
antitumoral compound
antitumoral
compound
Prior art date
Application number
MXPA04003674A
Other languages
English (en)
Inventor
Hidalgo Manuel
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MXPA04003674A publication Critical patent/MXPA04003674A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se dan programas de dosificacion mejorados para ecteinascidin 743 para el tratamiento de cancer.
MXPA04003674A 2001-10-19 2002-10-21 Uso mejorado de compuesto antitumoral en terapia de cancer. MXPA04003674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34841401P 2001-10-19 2001-10-19
PCT/US2002/033548 WO2003039571A1 (en) 2001-10-19 2002-10-21 Improved use of antitumoral compound in cancer therapy

Publications (1)

Publication Number Publication Date
MXPA04003674A true MXPA04003674A (es) 2004-07-23

Family

ID=23367939

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003674A MXPA04003674A (es) 2001-10-19 2002-10-21 Uso mejorado de compuesto antitumoral en terapia de cancer.

Country Status (15)

Country Link
US (1) US20050004018A1 (es)
EP (1) EP1435988A4 (es)
JP (1) JP2005509650A (es)
KR (1) KR20050038578A (es)
CN (1) CN1606449A (es)
AU (1) AU2002343548B2 (es)
BR (1) BR0213424A (es)
CA (1) CA2462502A1 (es)
HU (1) HUP0401903A3 (es)
IL (1) IL161430A0 (es)
MX (1) MXPA04003674A (es)
NO (1) NO20042035L (es)
PL (1) PL368458A1 (es)
RU (1) RU2306933C2 (es)
WO (1) WO2003039571A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
DE602004016376D1 (de) * 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
ES2326825T3 (es) * 2004-10-26 2009-10-20 Pharma Mar S.A., Sociedad Unipersonal Doxorubicina liposomal pegilada en combinacion con ecteinascidina 743.
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
PT2129396E (pt) * 2007-02-16 2013-11-18 Merrimack Pharmaceuticals Inc Anticorpos contra erbb3 e suas utilizações
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
NZ591137A (en) * 2008-08-15 2012-10-26 Merrimack Pharmaceuticals Inc Methods and systems for predicting response of cells to a therapeutic agent
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
RU2017129378A (ru) 2011-07-15 2019-02-04 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
US9943517B2 (en) 2012-11-13 2018-04-17 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
DE60111845T2 (de) * 2000-04-12 2006-04-27 Pharma Mar, S.A., Tres Cantos Ecteinaschidin derivate mit antikrebs wirkung
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid

Also Published As

Publication number Publication date
AU2002343548B8 (en) 2003-05-19
CA2462502A1 (en) 2003-05-15
BR0213424A (pt) 2004-12-14
RU2306933C2 (ru) 2007-09-27
KR20050038578A (ko) 2005-04-27
RU2004115110A (ru) 2005-03-10
IL161430A0 (en) 2004-09-27
JP2005509650A (ja) 2005-04-14
EP1435988A4 (en) 2008-01-09
PL368458A1 (en) 2005-03-21
HUP0401903A3 (en) 2008-07-28
US20050004018A1 (en) 2005-01-06
CN1606449A (zh) 2005-04-13
HUP0401903A2 (hu) 2005-01-28
WO2003039571A1 (en) 2003-05-15
NO20042035L (no) 2004-05-18
EP1435988A1 (en) 2004-07-14
AU2002343548B2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MY136520A (en) Novel compounds
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
IL164599A0 (en) Combination therapy for the treatment of cancer
AP2000001785A0 (en) Medicaments
PL354540A1 (en) Drugs for the treatment of malignant tumours
EP1446012A4 (en) Bacteriolytic combination therapy for the treatment of tumors
DE69905170D1 (en) Thiazolopyrimidinderivate
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
HK1060067A1 (en) Compositions for antitumour treatment containing ecteinascidin 743
ZA200408767B (en) Immunoconjugates for the treatment of tumours
HUP0500424A3 (en) Combination therapy for the treatment of cancer
HK1040983A1 (en) Quinones for treatment of diseases.
YU13301A (sh) Muskarinski agonisti i antagonisti
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
EP1185276A4 (en) ISOPHOSPHORAMIDE MUSTARD GAS ANALOGS AND THEIR USE
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
EP1303520A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
MXPA04005942A (es) Composiciones y metodos de sintaxina 3.
IL139144A0 (en) Mycobacterial inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal